Heidelberg Pharma AG (ETR:HPHA)

BRIEF

published on 04/29/2026 at 07:10, 1 day 4 hours ago

Heidelberg Pharma AG Reports Progress in Q1 2026

Financial Results Clinical Trials Heidelberg Pharma HDP-101 Biotech Development
PRESS RELEASE

published on 04/29/2026 at 07:05, 1 day 4 hours ago

Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2026
Heidelberg Pharma AG reports significant progress in the first quarter of 2026 financially and in clinical development, completion of Phase I clinical trial, milestone payments triggered, and extended cash reach

Clinical Development Phase I Trial Heidelberg Pharma AG Milestone Payments Financial Progress
BRIEF

published on 04/17/2026 at 09:43, 13 days 2 hours ago

Heidelberg Pharma Announces Executive Board Change

CFO Appointment Biotech Clinical Trial Heidelberg Pharma Executive Change
PRESS RELEASE

published on 04/17/2026 at 09:38, 13 days 2 hours ago

Heidelberg Pharma Announces Change in Executive Board
Heidelberg Pharma announces change in Executive Board as CFO Walter Miller departs end of April, Peter Willinger appointed as new CFO from 1 May 2026. Company specializes in developing Antibody Drug Conjugates (ADCs)

CFO Executive Board Heidelberg Pharma Antibody Drug Conjugates ADCs
BRIEF

published on 04/09/2026 at 14:31, 20 days 21 hours ago

Heidelberg Pharma Advances ADC Candidate HDP-101 to Phase II Trial

Clinical Research Heidelberg Pharma Phase II Trial Multiple Myeloma ADC HDP-101
PRESS RELEASE

published on 04/09/2026 at 14:26, 20 days 21 hours ago

EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma Determines Recommended Dose for Phase II Trial with ADC Candidate HDP-101
Heidelberg Pharma AG determines recommended Phase II dose for ADC candidate HDP-101 in multiple myeloma trial, plans Phase IIa initiation shortly

Heidelberg Pharma AG Multiple Myeloma ADC Candidate Phase II Dose Phase IIa Trial
BRIEF

published on 04/04/2026 at 10:12, 26 days 1 hour ago

Heidelberg Pharma to Showcase ADC Technology at AACR 2026

Heidelberg Pharma ADC Technology Prostate Cancer AACR 2026 HDP-103
PRESS RELEASE

published on 04/04/2026 at 10:07, 26 days 1 hour ago

Heidelberg Pharma to Present Data from its ADC Technology Platform at AACR Annual Meeting 2026
Heidelberg Pharma to present promising preclinical data of Amanitin-based ADC HDP-103 targeting mCRPC at AACR Annual Meeting 2026 in San Diego

Heidelberg Pharma Amanitin-based ADC ADC Technology Platform AACR Annual Meeting 2026 MCRPC
BRIEF

published on 03/26/2026 at 07:12, 1 month 4 days ago

Heidelberg Pharma Publishes 2025 Financial Results and 2026 Outlook

Financial Results Cost-cutting Measures Heidelberg Pharma ADC Technology 2026 Outlook
PRESS RELEASE

published on 03/26/2026 at 07:07, 1 month 4 days ago

Heidelberg Pharma Announces Financial Figures and Reports on Business Performance in 2025 and Outlook for 2026
Heidelberg Pharma AG reports financial figures, business performance in 2025, and outlook for 2026, including CEO appointment, cost-cutting program, and extended cash runway. Fast Track designation for HDP-101 by FDA

Financial Figures Outlook Business Performance Heidelberg Pharma Fast Track Designation

Published on 04/30/2026 at 08:00, 4 hours 2 minutes ago

Caledonia Mining Corporation Plc: Change of Chairman
Published on 04/30/2026 at 07:15, 4 hours 47 minutes ago

Route1 Reports Fiscal Year 2025 Results and Continued Transition Toward Recurring, Lifecycle-Based Revenue
Published on 04/30/2026 at 01:35, 10 hours 27 minutes ago

Kalo Gold Provides Update on High-Resolution Airborne Magnetic Survey at Vatu Aurum Project, Fiji
Published on 04/30/2026 at 01:15, 10 hours 47 minutes ago

Credissential Announces Shares Consolidation
Published on 04/30/2026 at 00:49, 11 hours 13 minutes ago

Fourth Quarter and Year-End 2025 Results

View all ACCESSWIRE

Published on 04/30/2026 at 11:50, 12 minutes ago

Amundi Physical Metals plc: UK Final Terms
Published on 04/30/2026 at 11:46, 16 minutes ago

Amundi Physical Metals plc: Final Terms
Published on 04/30/2026 at 11:31, 31 minutes ago

EQS-Adhoc: ATOSS Software SE: Planned change in executive leadership effective at year‑end 2026/2027
Published on 04/30/2026 at 11:16, 46 minutes ago

EQS-Adhoc: Mountain Alliance AG resolves on capital increase against cash contributions with exclusion of subscription rights to expand its portfolio in the Defence Tech sector
Published on 04/30/2026 at 11:07, 55 minutes ago

RIGSAVE S.p.A.: Shareholders' Meeting Approves 2025 Financial Statements under Italian Accounting Standards and Appoints New Corporate Bodies

View all EQS

Published on 04/30/2026 at 07:45, 4 hours 17 minutes ago

The Belgian State and ENGIE Group enter into exclusive negotiations for the acquisition by Belgium of ENGIE's nuclear activities
Published on 04/30/2026 at 07:30, 4 hours 32 minutes ago

New Gimv Anchor investment: acquisition of 5% shareholding in Azelis
Published on 04/30/2026 at 07:29, 4 hours 33 minutes ago

First Quarter Revenues 2026
Published on 04/29/2026 at 23:00, 13 hours 2 minutes ago

INFORMATION ON ANNUAL FINANCIAL STATEMENTS
Published on 04/29/2026 at 18:31, 17 hours 31 minutes ago

FIRST QUARTER 2026 TURNOVER

View all LES ECHOS COMFI WIRE

News